9/30/2013

UCB received the FDA's approval to market Cimzia, or certolizumab pegol, as a treatment for active psoriatic arthritis. The drug was previously approved for treatment of severe rheumatoid arthritis and for alleviating Crohn's disease symptoms.

Full Story:
Reuters

Related Summaries